BioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024. In the quarter to June 2026, revenue fell 58.5%, EPS fell 107.1%, free cash flow fell 342.0% and total debt rose 20.1%, each against the same quarter a year earlier.
Follow BNTX
BioNTech SE Sponsored ADR (BNTX) EV/Sales
As of 16 October 2026, BioNTech SE Sponsored ADR (BNTX) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 0.0× (September 2020) to 160× (December 2020); the current reading is higher than 51% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (37.51%) |
| FY2024 | 3.2× | 41.07% |
| FY2023 | 2.3× | 91.40% |
| FY2022 | 1.2× | (56.33%) |
| FY2021 | 2.7× | (91.68%) |
| FY2020 | 32.5× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.2× | 24.67% |
| Mar 2026 | 1.8× | (10.06%) |
| Dec 2025 | 2.0× | 2.22% |
| Sep 2025 | 2.0× | (39.61%) |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR | 1.8× |
| INCY Incyte Corporation compare | 3.1× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 6.0× |
| EXEL Exelixis, Inc. compare | 6.1× |
| GMAB Genmab A/S Sponsored ADR compare | 6.4× |
| ASND Ascendis Pharma A/S compare | 11.6× |
| RPRX Royalty Pharma PLC compare | 14.0× |
| INSM Insmed, Inc. compare | 18.1× |
| ROIV Roivant Sciences Ltd. compare | 2,742× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)